Hormone Therapy Statistics in US 2026 | Key Facts

What Is Hormone Therapy?

Hormone therapy — the medical administration of hormones to supplement, replace, or regulate the body’s own hormonal systems — is one of the broadest and most clinically diverse categories in all of modern medicine, encompassing treatments that serve radically different patient populations for radically different purposes but share the common mechanism of addressing conditions caused by hormonal deficiency, excess, imbalance, or mismatch. In its most widely used form, menopausal hormone therapy (MHT) — also historically known as hormone replacement therapy (HRT) — addresses the decline in estrogen and progesterone that accompanies the menopause transition, treating symptoms ranging from vasomotor events (hot flashes and night sweats) to genitourinary syndrome, mood disturbances, cognitive effects, bone density loss, and cardiovascular changes that follow from estrogen withdrawal. In a second major form, gender-affirming hormone therapy (GAHT) provides estrogen, progesterone, testosterone, and anti-androgenic medications to transgender and gender-diverse individuals to align physical characteristics with gender identity — a medically supported, evidence-based intervention endorsed by every major American medical organisation, including the American Medical Association, the American Psychological Association, the American Academy of Pediatrics, and the Endocrine Society. In a third significant form, hormone therapy for cancer treatment uses anti-estrogenic and anti-androgenic agents — tamoxifen, aromatase inhibitors, and androgen deprivation therapy — to slow or halt hormone-sensitive cancers, particularly breast cancer in women and prostate cancer in men. The total US market encompassing all these forms of hormone therapy is a multi-billion-dollar ecosystem that touches millions of Americans annually and is growing in both commercial and clinical importance.

As of March 29, 2026, hormone therapy in America is simultaneously undergoing a clinical renaissance and a political firestorm — depending on which population and which form of treatment is being discussed. For menopausal hormone therapy, the story is one of persistent underuse despite a growing body of evidence favouring its benefits for appropriate patients: a landmark PMC-published study in 2024 confirmed that MHT use declined from 26.9% of US postmenopausal women in 1999 to just 4.7% in 2020, a trajectory driven primarily by the Women’s Health Initiative (WHI) study’s 2002 findings that created an outsized fear of HRT that specialists now argue was partially misapplied to younger, healthier menopausal women. The Menopause Society has issued updated position statements supporting MHT use for appropriate candidates, and prescription rates have begun recovering — CDC data confirms over 12 million hormone therapy prescriptions were dispensed in the US in 2024 — but they remain far below the levels that clinical evidence would support. For gender-affirming hormone therapy, the context is almost entirely political: the Trump administration signed an executive order restricting GAHT access for youth under 19 on January 20, 2025, at least 26 states have enacted legislative bans on gender-affirming care for minors, and the Supreme Court’s June 2025 ruling in United States v. Skrmetti provided a complex legal framework that has left the access landscape fragmented and contested. And yet, as this article documents with verified data, the actual number of minors receiving gender-affirming medications — despite dominating political headlines for three years — is, according to Harvard researchers, “less than 0.1% of privately insured adolescents.”

Interesting Key Facts About Hormone Therapy Statistics in the US 2026

Source: PMC — “Menopausal Hormone Therapy Use Among Postmenopausal Women” (PMC11437377, NHANES 1999–2020 cross-sectional study, n=13,048, published September 2024);

The scale and context embedded in these key statistics tell two very different stories about hormone therapy in America — and understanding both simultaneously is essential for any accurate account of where the field stands in 2026. The menopausal hormone therapy story is primarily one of a clinically validated treatment in severe underuse: only 4.7% of postmenopausal women were using MHT as of 2020, despite the treatment being the most effective available for vasomotor and genitourinary menopausal symptoms, and despite robust data from the Menopause Society showing that the benefits outweigh the risks for most healthy women under 60 who initiate MHT within 10 years of menopause. The WHI study’s legacy — a 2002 finding that was broadly applied to populations for whom the risk-benefit calculation is very different from the older, longer-menopausal women who were actually studied — created a chilling effect on both prescribing and patient acceptance that has persisted for more than two decades and which practitioners describe as one of the great medical overcorrections of recent history. The recovery is underway — over 12 million prescriptions in 2024 — but the gap between current use and evidence-supported optimal use remains enormous.

The gender-affirming hormone therapy story, by contrast, is one in which a politically tiny practice — less than 0.1% of privately insured adolescents ever received gender-affirming medications across an entire five-year study period — has been at the centre of one of the most intense legislative and judicial battles in American healthcare since Roe v. Wade. The Harvard/JAMA Pediatrics finding that fewer than 1,000 adolescents accessed puberty blockers and fewer than 2,000 ever accessed hormones in a database of more than 5.1 million privately insured youth from 2018 to 2022 should be one of the most widely known statistics in the national debate — but it has received a fraction of the attention of the legislative activity it directly contextualises. Lead researcher Landon Hughes was explicit: “The politicization of gender-affirming care for transgender youth has been driven by a narrative that millions of children are using hormones and that this type of care is too freely given. Our findings reveal that is not the case.”

Menopausal Hormone Therapy (MHT) Statistics in the US 2026

MHT Prevalence, Trends & Demographics — US 1999–2026

Source: PMC — “Menopausal Hormone Therapy Use Among Postmenopausal Women” (PMC11437377, September 2024, cross-sectional NHANES study 1999–2020, 13,048 participants); JAMA Health Forum (September 6, 2024); The Menopause Society (press release, September 4, 2024); USPSTF (2022); PMC — Korean Society of Menopause Guidelines 2025 (PMC12438153, published 2025); Market Data Forecast North America HRT Market (2024); National Osteoporosis Foundation

The MHT prevalence data from the NHANES cross-sectional study — the most comprehensive nationally representative analysis of prescription-based MHT use in the post-WHI era, drawing on 13,048 US postmenopausal women across two decades — tells a story of what happens when a single large clinical trial produces findings that are then applied far more broadly than the evidence supports. The Women’s Health Initiative, which studied relatively older postmenopausal women (average age 63 at enrolment) who started hormones more than 10 years after menopause, found elevated risks of certain adverse events in that specific population. What followed was an almost complete collapse of HRT prescribing — and, as the PMC data confirms, a 22-percentage-point decline in use between 1999 and 2020 — that swept up younger, healthier menopausal women for whom the risk-benefit calculation is fundamentally different. The Menopause Society’s updated position — that for most healthy women under 60 who begin MHT within 10 years of menopause, the benefits outweigh the risks — represents the medical consensus that has emerged from a careful re-reading of the WHI data and subsequent trials. But this reassessment has been slow to reach patients and prescribers, and the persistent racial and socioeconomic disparities in MHT use — with non-Hispanic Black women at just 0.5% use in 2020 versus non-Hispanic White women at 5.9% — add a health equity dimension to the underuse story that compounds the clinical failure.

The JAMA Health Forum’s September 2024 characterisation of MHT as “vastly underused” — echoing The Menopause Society’s long-standing position — is not a fringe perspective but the emerging mainstream view in academic menopause medicine. The 6,000 women who reach menopause every day in America, and the over 50 million women aged 51 or older who are in or past the typical menopause window, represent a clinical opportunity of enormous scale. If MHT use even partially recovered toward the levels that evidence supports — say, to 15% of eligible women rather than 4.7% — the implications for quality of life, bone fracture rates, cardiovascular outcomes, and potentially cognitive health would be substantial. That recovery is being driven both by updated clinical guidelines and by a growing cultural conversation, catalysed by high-profile advocates in media, social platforms, and public health, that has made menopause and its treatment a mainstream rather than hidden conversation for the first time in decades.

Gender-Affirming Hormone Therapy (GAHT) Statistics in the US 2026

GAHT — Users, Access, Restrictions & Clinical Outcomes Data

Source: Harvard T.H. Chan School of Public Health / Harvard Gazette (January 6, 2025)

The gender-affirming hormone therapy data in 2026 operates in a context where the clinical evidence and the political response are in profound tension, and where the specific numbers — grounded in peer-reviewed research — are essential for any accurate public understanding. The Harvard/JAMA Pediatrics study is the definitive empirical anchor: in more than 5.1 million privately insured adolescents aged 8 to 17, observed from 2018 to 2022, fewer than 18,000 had any gender-related diagnosis, and of those, fewer than 1,000 ever received puberty blockers and fewer than 2,000 ever received gender-affirming hormones across the entire five-year period. These are not numbers from a small convenience sample — they are drawn from insurance claims across all 50 states, representing one of the largest-ever studies of adolescent GAHT access. No patients under age 12 received hormones. The timing of care among those who did receive it was consistent with WPATH, Endocrine Society, and AAP standards — confirming appropriate clinical gatekeeping rather than the “easy access” narrative that has driven legislative action. The Harvard researchers described these findings as showing “we are not seeing inappropriate use of this sort of care.”

The mental health outcomes data for GAHT is equally important for contextualising the debate. The JMIR 2025 longitudinal cohort study of 342 adults beginning GAHT via telehealth found significant improvements in depression and anxiety scores within just three months of initiating treatment — a clinically meaningful change in a population that experienced those mental health outcomes through a controlled prospective design rather than retrospective self-report. The PMC analysis of 92,329 gender minority individuals who received gender-affirming hormones and/or surgery found 98% and 97% reporting increased life satisfaction respectively — among the highest patient-reported outcomes of any medical intervention in published literature. Against this clinical backdrop, the JAMA Network Open finding that 21.3% of transgender adults surveyed reported suicidal ideation — active or passive — specifically associated with the prospect of losing access to gender-affirming care documents the mental health stakes of access restrictions in direct, quantified terms that go far beyond advocacy and represent a genuine clinical signal.

HRT Market & Economic Statistics in the US 2026

Hormone Replacement Therapy Market — Size, Growth & Segments

Source: Fortune Business Insights — Hormone Replacement Therapy Market Report (2025); FactMR — HRT Market Forecast (2025–2036); Market Data Forecast — North America HRT Market (2024)

The HRT market statistics reveal the enormous commercial gap between clinical need and current utilisation — and why analysts project robust sustained market growth through the 2030s. With more than 50 million US women aged 51 or older, a North American market currently valued at under $9 billion, and a usage rate of under 5% of postmenopausal women, the headroom for growth is extraordinary. Every percentage point increase in MHT adoption among eligible US women represents approximately 500,000 additional patients at typical prescription costs, making the potential market expansion from a clinical normalisation of MHT something that pharmaceutical companies, telehealth platforms, and retail pharmacy chains are actively positioning for. The 7.12% projected North American CAGR through 2033 reflects this optimism — driven not just by rising awareness but by structural changes in how menopausal care is delivered, including the rapid expansion of menopause-specialised telehealth services that have made prescribing accessible to women whose primary care physicians may lack expertise in or enthusiasm for MHT management.

The market’s heavy concentration in estrogen and progesterone formulations (56% share) and oral administration (41%) masks a complex and evolving competitive landscape below the headline numbers. The transdermal patch, vaginal ring, topical gel, and intrauterine delivery segments are all growing as evidence emerges that non-oral estrogen delivery avoids the first-pass hepatic metabolism that may account for some of the cardiovascular and thromboembolic risks observed with oral formulations. The testosterone replacement therapy segment — encompassing both male hypogonadism treatment and the growing use of low-dose testosterone for menopausal women — is one of the fastest-expanding subsegments, driven by direct-to-consumer telehealth prescribing platforms and a growing body of evidence for testosterone’s role in libido, energy, cognition, and body composition across the gender spectrum. The major pharmaceutical players — Novo Nordisk, Pfizer, Bayer, Eli Lilly, and AbbVie — are all investing in product line extensions, new delivery systems, and patient education programmes designed to accelerate the market normalisation of hormone therapy as a standard element of healthy ageing care.

Hormone Therapy Policy & Access Statistics in the US 2026

State Laws, Federal Actions & Access Landscape — Menopausal & Gender-Affirming HRT

Source: Williams Institute / UCLA — “Impact of Ban on Gender-Affirming Care on Transgender Minors” (March 21, 2025); USPSTF (2022); The Menopause Society (2022–2024); JMIR (2025); PMC NHANES (September 2024); Market Data Forecast (2024); Fortune Business Insights (2025)

The policy landscape governing hormone therapy in America in 2026 is the most complex and contested in the history of the field — with menopausal HRT facing the aftermath of regulatory conservatism (the USPSTF’s continued warning against using MHT for chronic disease prevention) while simultaneously recovering through updated clinical society guidance, and gender-affirming hormone therapy facing the most aggressive political restriction campaign in US medical history. The legal architecture following United States v. Skrmetti — in which the Supreme Court’s June 2025 ruling upheld Tennessee’s gender-affirming care ban for minors as constitutionally permissible under the Equal Protection Clause — has shifted the landscape decisively for minor access, with state bans now broadly presumed constitutional and litigation efforts refocusing on other legal theories including substantive due process and parental rights arguments. The Williams Institute’s finding that approximately 110,300 transgender youth now live in states with enacted bans means that more than one-third of the estimated 300,100 transgender adolescents in the US are in jurisdictions where access to gender-affirming medications is now legally prohibited.

The telehealth revolution is the most consequential structural development in hormone therapy access for both populations. For menopausal women, direct-to-consumer platforms — including Midi, Alloy, Evernow, and others — have created pathways to MHT prescribing that bypass the historic access barriers of finding a menopause-competent physician, scheduling an in-person appointment, and navigating primary care gatekeeping from providers without specialised expertise. The FOLX Health GAHT telehealth study covering 43 states — published in JMIR in 2025 — documents how a similar telehealth model has expanded gender-affirming hormone access for adults into geographic areas where in-person gender-affirming care providers are scarce. The finding that 31.7% of transgender adults surveyed said they would consider DIY hormone therapy if supervised access were further restricted — confirmed by the JAMA Network Open 2025 study — highlights the public health consequence of access restriction policies: when medically supervised hormone therapy becomes inaccessible, a significant proportion of patients report they would pursue unsupervised alternatives, with the attendant health risks that come from pharmaceutical sourcing of uncertain quality and management without clinical monitoring.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.